Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 13
Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.
Video content above is prompted by the following:
Can you share some of the biggest unmet need(s) or treatment gaps that still exist for patients with breast cancer who are receiving antibody-drug conjugates and some practice pearls you wish to share with your community colleagues?